ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 6, 2021

10:15AM-10:30AM: Abstract Number: 0448

Bone Microarchitecture Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) as Predictor of Incident Fracture in Rheumatic Disease Patients on Long-term Glucocorticoid- a Five-year Longitudinal Study

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)

10:15AM-10:30AM: Abstract Number: 0452

Total-Body 18F-FDG PET/CT Imaging: A Tool for Diagnosis and Quantifying Inflammatory Burden of Psoriatic Arthritis

Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)

10:30AM-10:45AM: Abstract Number: 0462

Remotely Delivered Cognitive Behavioural and Personalised Exercise Interventions Reduce Fatigue Severity and Impact in Inflammatory Rheumatic Diseases: Results from a Multi-centre Randomised Controlled Parallel Group Trial

Abstracts: Health Services Research (0462–0465)

10:30AM-10:45AM: Abstract Number: 0458

Single Cell Profiling Reveals a Wnt-mediated Transcriptional Gradient That Drives Inflammation in Rheumatoid Arthritis Synovial Fibroblast Pathology

Abstracts: RA – Etiology & Pathogenesis (0458–0461)

10:30AM-10:45AM: Abstract Number: 0466

Subclinical Large Vessel Vasculitis in Polymyalgia Rheumatica

Abstracts: Imaging of Rheumatic Diseases (0466–0469)

10:45AM-11:00AM: Abstract Number: 0467

Assessing the Extent of Lumbosacral Spinal Urate Deposition in Patients with Tophaceous and Nontophaceous Gout Compared with Non-gout Controls Using Dual-Energy CT (DECT)

Abstracts: Imaging of Rheumatic Diseases (0466–0469)

10:45AM-11:00AM: Abstract Number: 0459

CCN1: An Angiogenic Actor Implicated in the Structural Damages of Rheumatoid Arthritis

Abstracts: RA – Etiology & Pathogenesis (0458–0461)

10:45AM-11:00AM: Abstract Number: 0453

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Integrated Results from 2 Phase 3, Randomized, Double-blind Clinical Trials for CsDMARD-IR and Bio-IR Patients

Plenary I (0453–0457)

10:45AM-11:00AM: Abstract Number: 0463

Treatment Persistence Among Medicare Beneficiaries with Seropositive Rheumatoid Arthritis Initiating Biologic or Targeted Synthetic DMARDs

Abstracts: Health Services Research (0462–0465)

11:00AM-11:15AM: Abstract Number: 0474

Correlation of Fibromyalgia Survey Questionnaire and Quantitative Sensory Testing Among Patients with Active Rheumatoid Arthritis

Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)

11:00AM-11:15AM: Abstract Number: 0468

During Development of Rheumatoid Arthritis, Intermetatarsal Bursitis May Occur Before Clinical Joint Swelling: A Large MRI Study in Patients with Clinically Suspect Arthralgia

Abstracts: Imaging of Rheumatic Diseases (0466–0469)

11:00AM-11:15AM: Abstract Number: 0470

Inhibition of Toll-Like Receptor 7 (TLR7) with the Potent and Selective Inhibitor of Human TLR7 and TLR8 BMS-986256 Provides Robust Efficacy in Murine Lupus Models, Reversing Established Disease

Abstracts: SLE – Animal Models (0470–0473)

11:00AM-11:15AM: Abstract Number: 0454

Lupus Nephritis Mortality in the United States, 1999-2019: Profound Disparities by Race/Ethnicity and Place of Residence and a Recent Worsening Trend

Plenary I (0453–0457)

11:00AM-11:15AM: Abstract Number: 0460

Single-cell Profiling of B and T Cell Repertoire and Gene Expression in the RA Synovium Reveals Tissue Specific Clonal Expansion

Abstracts: RA – Etiology & Pathogenesis (0458–0461)

11:00AM-11:15AM: Abstract Number: 0464

The Impact of Timely Post-Discharge Follow-up on Readmission Risk Among Patients with Systemic Lupus Erythematosus

Abstracts: Health Services Research (0462–0465)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].